Cargando…

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales:	Cafforio, Luciana, Raponi, Sara, Cappelli, Luca Vincenzo, Ilari, Caterina, Soscia, Roberta, De Propris, Maria Stefania, Mariglia, Paola, Rigolin, Gian Matteo, Bardi, Antonella, Peragine, Nadia, Piciocchi, Alfonso, Arena, Valentina, Mauro, Francesca Romana, Cuneo, Antonio, Guarini, Anna, Foà, Robin, Del Giudice, Ilaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719070/ https://www.ncbi.nlm.nih.gov/pubmed/34647439 http://dx.doi.org/10.3324/haematol.2020.263715

Ejemplares similares

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
por: Puzzolo, Maria Cristina, et al.
Publicado: (2021)

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?
por: Del Giudice, Ilaria, et al.
Publicado: (2019)

Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia
por: Marinelli, Marilisa, et al.
Publicado: (2016)

Sialylation regulates migration in chronic lymphocytic leukemia
por: Natoni, Alessandro, et al.
Publicado: (2023)

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
por: Visentin, Andrea, et al.
Publicado: (2022)

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
por: Rigolin, Gian Matteo, et al.
Publicado: (2023)

“Hemophagocytic Lymphohistiocytosis after EBV reactivation and ibrutinib treatment in relapsed/refractory Chronic Lymphocytic Leukemia”
por: Cavallari, Maurizio, et al.
Publicado: (2017)

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia
por: Voltan, Rebecca, et al.
Publicado: (2016)

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019)

The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
por: Visentin, Andrea, et al.
Publicado: (2019)

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
por: Fazio, F., et al.
Publicado: (2023)

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study
por: Bomben, Riccardo, et al.
Publicado: (2023)

Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances
por: Della Starza, Irene, et al.
Publicado: (2019)

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
por: Mauro, Francesca Romana, et al.
Publicado: (2021)

Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: An Italian Monocentric Experience
por: Fazio, Francesca, et al.
Publicado: (2023)

The complex karyotype landscape in chronic lymphocytic leukemia allows the refinement of the risk of Richter syndrome transformation
por: Visentin, Andrea, et al.
Publicado: (2021)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
por: Rigolin, Gian Matteo, et al.
Publicado: (2017)

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
por: Innocenti, Idanna, et al.
Publicado: (2022)

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells
por: Secchiero, Paola, et al.
Publicado: (2017)

Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
por: Cuneo, Antonio, et al.
Publicado: (2018)

High rate of minimal residual disease responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2)
por: Mauro, Francesca R., et al.
Publicado: (2020)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia
por: Guarini, Anna, et al.
Publicado: (2023)

Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
por: Assanto, Giovanni Manfredi, et al.
Publicado: (2023)

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation
por: Puzzolo, Maria Cristina, et al.
Publicado: (2022)

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study
por: Cuneo, Antonio, et al.
Publicado: (2020)

tpHusion: An efficient tool for clonal pH determination in Drosophila
por: Gupta, Avantika, et al.
Publicado: (2020)

A Tangle of Genomic Aberrations Drives Multiple Myeloma and Correlates with Clinical Aggressiveness of the Disease: A Comprehensive Review from a Biological Perspective to Clinical Trial Results
por: Sessa, Mariarosaria, et al.
Publicado: (2020)

Utility of Flow Cytometry Ascitic Fluid Analysis for Rapid Diagnosis of B-Cell Peritoneal Lymphomatosis
por: Bisegna, Maria Laura, et al.
Publicado: (2022)

TP53 variants in p53 signatures and the clonality of STICs in RRSO samples
por: Akahane, Tomoko, et al.
Publicado: (2022)

P861: SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY
por: Natoni, A., et al.
Publicado: (2022)

Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
por: Siddiqui, Maria Tariq, et al.
Publicado: (2021)

Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma
por: Martello, M., et al.
Publicado: (2022)

Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients
por: Chan, Thomas Sau-Yan, et al.
Publicado: (2017)

P1232: NON-INVASIVE MINIMAL RESIDUAL DISEASE ANALYSIS BY IMMUNOGLOBULIN GENE REARRANGEMENTS ON CIRCULATING TUMOR DNA PREDICTS THE OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Soscia, Roberta, et al.
Publicado: (2023)

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia
por: Della Starza, Irene, et al.
Publicado: (2023)

Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tp90dqfuod5a22e9uo0j5ng1jb